TSTickerStar
Company alerts/CLLS
CLLS company alerts

CLLS updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for CLLS. Subscribe to CLLS alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent CLLS alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

EarningsOfficial company source

Cellectis Reports Q3 2026 Results; Announces Strategic Pivot to In Vivo Gene Editing

Cellectis S.A. reported a net loss of $101.1 million for the nine-month period ended September 30, 2026, compared to a net loss of $41.3 million in the prior-year period, as revenues declined 76% to $14.8 million driven by lower activity under the AstraZeneca collaboration. The company announced a strategic transformation to become an in vivo gene editing company focused on chronic diseases, exiting development of lasme-cel and eti-cel while advancing.HEAL-101 and.HEAL-201 programs. The company recognized $26.8...

Read source-backed brief
Investor eventInvestor relations

Cellectis to Report Third Quarter 2026 Results on November 12, 2026

Cellectis will report third quarter 2026 financial results for the period ended September 30, 2026 on November 12, 2026 after the close of the U.S. market. An investor conference call and webcast will follow on November 13, 2026 at 8:00 a.m. ET / 2:00 p.m. CET, with conference ID CLLSQ3. The filing contains no reported financial results or guidance.

Read source-backed brief